|
Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors. |
|
|
Consulting or Advisory Role - Bayer; Sandoz |
Speakers' Bureau - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz |
|
|
Employment - Beam Therapeutics (I); Bluebird Bio (I); Kymera; Pfizer |
Stock and Other Ownership Interests - Alnylam (I); Beam Therapeutics (I); Bluebird Bio (I); Kymera; Pfizer |
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I) |
|
|
|
|
Stock and Other Ownership Interests - Kymera |
Research Funding - Kymera |
Patents, Royalties, Other Intellectual Property - AstraZeneca; Blueprint Medicines; Kyaera Therapeutics |
Travel, Accommodations, Expenses - Kymera |
|
|
|
Stock and Other Ownership Interests - Kymera |
Patents, Royalties, Other Intellectual Property - Presage Biosciences |
Travel, Accommodations, Expenses - Kymera |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Epizyme; Kymera |
|
|
|
|
Stock and Other Ownership Interests - Kymera |